Familial hypoaldosteronism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:427OMIM:203400E27.4
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial hypoaldosteronism is a rare inherited disorder of adrenal steroid biosynthesis characterized by deficient production of aldosterone, the principal mineralocorticoid hormone responsible for regulating sodium and potassium balance in the body. The condition primarily affects the renin-angiotensin-aldosterone system and can be caused by defects in different enzymatic steps of aldosterone synthesis. Two main forms are recognized: type I, caused by mutations in the CYP11B2 gene (encoding aldosterone synthase, also known as corticosterone methyl oxidase), which can be further subdivided into corticosterone methyl oxidase type I (CMO I) and type II (CMO II) deficiencies; and other rarer forms. The disorder predominantly affects the kidneys' ability to retain sodium and excrete potassium, leading to electrolyte imbalances. Clinical features typically present in infancy or early childhood and include failure to thrive, dehydration, salt-wasting episodes, hyponatremia (low blood sodium), hyperkalemia (high blood potassium), and metabolic acidosis. In severe cases, particularly in neonates and infants, life-threatening salt-wasting crises with vomiting, poor feeding, and cardiovascular collapse may occur. Interestingly, the clinical severity often improves with age, and many affected adults may be relatively asymptomatic or only mildly affected, likely due to compensatory mechanisms for sodium retention that mature over time. Treatment focuses on correcting the mineralocorticoid deficiency and electrolyte imbalances. In infancy and early childhood, management typically includes sodium chloride supplementation and, in some cases, fludrocortisone (a synthetic mineralocorticoid). As patients grow older, the need for treatment often decreases, and some adults may not require ongoing therapy. Regular monitoring of serum electrolytes and growth parameters is important, particularly during childhood. Genetic counseling is recommended for affected families.

Clinical phenotype terms— hover any for plain English:

Renal salt wastingHP:0000127Increased circulating renin concentrationHP:0000848Adrenal insufficiencyHP:0000846Decreased circulating aldosterone concentrationHP:0004319HypovolemiaHP:0011106Orthostatic hypotensionHP:0001278Proximal renal tubular acidosisHP:0002049Decreased urinary potassiumHP:0012364
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Familial hypoaldosteronism.

View clinical trials →

No actively recruiting trials found for Familial hypoaldosteronism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Familial hypoaldosteronism community →

No specialists are currently listed for Familial hypoaldosteronism.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Familial hypoaldosteronism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial hypoaldosteronismForum →

No community posts yet. Be the first to share your experience with Familial hypoaldosteronism.

Start the conversation →

Latest news about Familial hypoaldosteronism

No recent news articles for Familial hypoaldosteronism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Familial hypoaldosteronism

What is Familial hypoaldosteronism?

Familial hypoaldosteronism is a rare inherited disorder of adrenal steroid biosynthesis characterized by deficient production of aldosterone, the principal mineralocorticoid hormone responsible for regulating sodium and potassium balance in the body. The condition primarily affects the renin-angiotensin-aldosterone system and can be caused by defects in different enzymatic steps of aldosterone synthesis. Two main forms are recognized: type I, caused by mutations in the CYP11B2 gene (encoding aldosterone synthase, also known as corticosterone methyl oxidase), which can be further subdivided int

How is Familial hypoaldosteronism inherited?

Familial hypoaldosteronism follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial hypoaldosteronism typically begin?

Typical onset of Familial hypoaldosteronism is neonatal. Age of onset can vary across affected individuals.